top of page

RECENT POSTS: 

FOLLOW ME:

  • Facebook Clean Grey
  • Twitter Clean Grey
  • Instagram Clean Grey

Moderna’s Coronavirus Vaccine Trial Shows ‘Positive’ Data: All 45 People Producing Antibodies


Moderna CEO Stephane Bancel speaks at a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House, Monday, March 2, 2020.

Moderna’s closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday, sending the company’s shares surging more than 39% in premarket trading.

Each participant was assigned to receive a 25 microgram, 100 mcg or 250 mcg dose, with 15 people in each dose group. Study participants received two doses of the potential vaccine via intramuscular injection in the upper arm approximately 28 days apart. Data on a second dose was not available for the 250 mcg group, the company said.

At day 43, or two weeks following the second dose, levels of binding antibodies in the 25 mcg cohort were at the levels generally seen in blood samples from people who recovered from the disease, the company said. Antibodies in the 100 mcg had antibodies that “significantly exceeded levels” in recovered patients.

The vaccine also produced neutralizing antibodies against Covid-19 in at least eight participants, the company said. Experts have said neutralizing antibodies appear to be important in acquiring protection.

Four participants were assigned to receive a 25 microgram dose, while the other four received 100 mcg.

Levels of neutralizing antibodies were at or above levels seen in blood samples, the company said. Data on neutralizing antibodies for the other participants were not yet available, Moderna said.

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg,” Tal Zaks, the chief medical officer at Moderna, said in s statement.

“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” Zaks added.

Scientists hope the antibodies provide some degree of protection against getting COVID-19, but they can’t say that definitively yet since it hasn’t been studied and some patients appear to have been reinfected after recovering from the virus.

Source: Read more from nbcnewyork.com

bottom of page